BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices
Austin, TX -- BioStable Science & Engineering, Inc., (“BioStable”) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair. With CE Mark approval of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable will be able to offer surgeons within the European Union a comprehensive portfolio of aortic valve repair solutions that address all forms of aortic valve insufficiency. In addition, BioStable announced that over 1,000 patients worldwide have now been treated using HAART Aortic Annuloplasty Devices.
Bicuspid aortic valve (BAV) is the most common congenital heart defect, affecting up to 2% of the population, and carries a significant risk of cardiovascular complications. Approximately 53% of BAV patients require aortic valve surgery within 25 years of being diagnosed.[1] Most BAV patients undergo aortic valve replacement between 40 and 60 years of age, subjecting them to increased risk of reoperation or complications associated with valve replacement technologies. [2] Valve repair is an attractive alternative to valve replacement for bicuspid aortic valve insufficiency and the HAART 200 Device has been specifically designed to facilitate BAV repair.
“People with BAV tend to present while still young. With many years of life still ahead, they are hoping to continue their normal active lifestyle, avoid life-long anticoagulation and the thromboembolic risk of a prosthetic valve that accrues for the rest of their lives. BAV repair offers freedom from these challenges, but the techniques to achieve success with varying subtypes have lacked standardization, leaving the majority of BAV insufficiency considered unrepairable and thus replaced. The HAART devices assign proper geometry to the valve and allow surgeons to apply a well standardized methodology to achieve excellent valve function. Over the last several years we have refined a set of techniques that are easily taught and reproduced,” said Chief of Cardiothoracic Surgery at Franciscan Health, Marc W. Gerdisch, MD. “Later this month, we will present on the experience from 15 institutions with 70 patients at the American Association for Thoracic Surgery Annual Meeting.”
The body of published clinical evidence demonstrating the excellent outcomes achievable with the HAART devices has been rapidly increasing. To date, there are more than 38 peer-reviewed publications covering over 300 patient lives with a maximal follow-up of 88 months. This collection of clinical information comes from over 30 institutions across the US and Europe.
“The latest mid-term follow-up data are compelling and suggest good durability of aortic valve repair with the HAART devices. The latest HAART data demonstrates >80% of patients are alive and free from reoperation at a maximal follow-up of 88 months, similar to other repair strategies [3]. The difference is that, with the HAART system, it is possible to repair over 90% of non-calcified AI pathologies [4]” said Dr. J. Scott Rankin, Professor of Surgery at West Virginia University Heart and Vascular Institute, and inventor of the HAART Aortic Repair Technologies.
John Wheeler, President, and CEO of BioStable Science & Engineering concluded by saying: “The CE Mark approval for the HAART 200 Aortic Annuloplasty Device completes the HAART portfolio in Europe and allows surgeons to now address all types of aortic valve configurations with AI. The combination of this approval with the growing positive clinical evidence indicates the value that aortic ring annuloplasty provides to surgeons and patients. We expect to perform our first cases with the HAART 200 Devices in EU in a targeted launch of the product later this year.”
Related news
-
Outlook on the Medical Ceramics Global Market to 2026 - Identify Key Drivers and Challenges
According to Fast. MR research the report titled Global Medical Ceramics Market provides comprehensive information regarding influential factors. Data included in the report has been curated by our team of industry experts, considering relevant information about the market. This report discusses the growth and trends of various regions and segments of the market. Information such as market drivers, restraints, opportunities, trends, gross revenue, average product/service price, and market share of major players...
-
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications
MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, offering the NanoTherm Therapy System for the treatment of brain tumors, supports World Brain Tumor Day on June 8th, 2021 and informs about various virtual patient events to raise awareness for this devastating disease. “Though rare compared to other types of cancers, brain tumors, especially glioblastomas, are a devastating and mostly fatal disease. Despite...
-
Scivita Medical Raises Nearly RMB0.4 Billion in Series a Funding Round and Strives to Build a World-leading Platform for Innovative Products in Endoscope and Related Fields
Scivita Medical Technology Co., Ltd. (`Scivita Medical*) today announced that it has raised nearly RMB0.4 Billion in Series A funding round, which has become one of the highest financing projects in the field of endoscope in China in recent years. The investment was jointly led by GL Ventures and Lilly Asia Ventures with contribution from Matrix Partners China, Medtronic, Chengwei Capital and Shanghai Innochip Investment The successful completion of the Series A funding round reflects the recognition of Scivita...
-
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC), in combination with chemotherapy as neoadjuvant (pre-operative) treatment, then continuing as a...
-
PhotoniCare Announces Rebranding of First-in-Class Technology for Imaging the Middle Ear, Now called OtoSight Middle Ear Scope
PhotoniCare, Inc., a company dedicated to revolutionizing healthcare by providing healthcare providers with better diagnostic tools, today announced that it is rebranding its middle ear scope to OtoSight™ Middle Ear Scope (formerly TOMi™ Scope). In preparation for the 2021 commercial launch, the OtoSight™ Middle Ear Scope brand name is well-positioned to convey the product’s unique ability to non-invasively see through the eardrum and assess the middle ear space. Using optical coherence...
Customer comments
No comments were found for BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices. Be the first to comment!